VHIRhttp://www.vhir.org/salapremsa/noticies/noticies_paginacio.asp?page=1&mv1=5&mv2=3es-esIRHUV15Sant Jordi al VHIR (23/04/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=101&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0101\2014_0101_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Un any més els investigadors del Vall d’Hebron Institut de Recerca (VHIR) s’han sumat a la celebració de la Diada de Sant Jordi i han demostrat la seva gran creativitat amb les fotografies i imatges que ens han enviat relacionades amb la ciència i la llegenda de Sant Jordi. Aquest any però, persones de fora del Vall d’Hebron també han volgut compartir amb nosaltres imatges sobre aquesta tradició tan especial a Catalunya. Voleu veure totes les imatges? Les hem penjat totes al nostre perfil de Facebook en aquest enllaç on les podeu veure encara que no tingueu compte personal de Facebook. Les dues fotografies que sumin més vots al Facebook i al Twitter del VHIR fins el dilluns 28 d’abril a les 10 del matí guanyaran una tablet patrocinada per Pista Cero. </td></tr></table>comunica@vhir.org (VHIR)Wed, 23 Apr 2014 00:00:00 GMTCataluña quiere ponerse al frente en la detección precoz de las inmunodeficiencias graves en recién nacidos (22/04/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=96&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0096\2014_0096_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> En el marco de la Semana Mundial de las IDP que se celebra del 22 al 29 de abril, la Asociación Catalana de Déficits Inmunitarios Primarios (ACADIP), juntamente con la Unidad de Patología Infecciosa e Inmunodeficiencias Pediátricas del Hospital Universitario Vall d’Hebron, el Vall d’Hebron Institut de Recera (VHIR), el Hospital Sant Joan de Déu y el Grupo de Trabajo en Inmunodeficiencias de las Sociedades Catalanas de Pediatría e Inmunología, llevarán a cabo un programa de actividades informativas y lúdicas para dar a conocer las inmunodeficiencias primarias (IDP) y acercar la realidad de los ‘niños burbuja’ a la sociedad. La inmunodeficiencia combinada grave es una enfermedad tratable en la cual un bebé no desarrolla un sistema inmunitario normal. Se trata de un problema de salud grave, asintomático en el nacimiento, asociado a infecciones graves. El Dr. Pere Soler-Palacín, investigador del grupo de Infección en el Paciente Pediátrico Inmunodeprimido del VHIR, explica que “hay que tener presente que si no se realiza el trasplante de precursores hematopoéticos a tiempo, los niños con estas enfermedades mueren”. No obstante, si se trata en las primeras semanas o meses de vida, la supervivencia de niños trasplantados en los primeros tres meses es de más del 90%, frente al 66% de los trasplantes realizados posteriormente. Esta es la clave del examen neonatal que ofrecería una rápida detección de la enfermedad a los pocos días de vida del bebé. La detección de los TRECs, una técnica que permite salvar vidas El Departamento de Salud de la Generalitat de Catalunya está valorando la posibilidad de implantar la prueba de detección de los TRECs (T cell receptor excision circles) –marcadores de la función del timus, una glándula imprescindible para el correcto funcionamiento del sistema inmunitario– para la detección de las IDPs más graves, las inmunodeficiencias combinadas graves o ‘niños burbuja’, que ya se lleva a cabo en más de 10 estados de los EEUU. Esta técnica permite detectar en la sangre de la prueba del talón el número de TRECs que se crean durante el funcionamiento normal de la maduración de estas células, pero que están absentes o son muy reducidos en el caso de los niños burbuja. Es una prueba muy sensible y efectiva, con una tasa de falsos positivos muy por debajo del 1%, según la Immune Deficiency Foundation. Seminario en el VHIR <span style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-serif; font-style: normal; font</td></tr></table>comunica@vhir.org (VHIR)Tue, 22 Apr 2014 00:00:00 GMTThe Bioinformatics Barcelona platform, in which VHIR participates, presents its Strategic Plan (22/04/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=98&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0098\2014_0098_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Bioinformatics Barcelona (BiB) platform, created in 2013 to promote multidisciplinary research, education, research and transfer of the knowledge and technologies in the field of bioinformatics, has introduce its Strategic Plan in an event chaired by Antoni Castellà, Secretary of Universities and Research of Catalonia. In the event, attended by Dr. Joan Comella, director of the Vall d'Hebron Institute of Research (VHIR), have been defined the main priorities in the areas of visibility, training, internal and external collaboration and the research and transfer of knowledge as strategic priorities. Bioinformatics is an area of research in which computer science and IT are used to process biological data. Nowadays, in Catalonia there is a real lack of experts in this area of knowledge and that’s the reason why it’s necessary to make an effort in this specialty from the point of view of research as well as from the point of view of training and above of all is necessary to enhance the visibility of bioinformatics in the region. The BiB aims to position Barcelona as a world reference in bioinformatics, through cooperation between universities, research centers and other public and private entities. The BiB has the support of 44 Catalan institutions including 10 universities, 3 large infrastructures, 12 pharmaceutical and computer companies and 13 research centers, including the VHIR. </td></tr></table>comunica@vhir.org (VHIR)Tue, 22 Apr 2014 00:00:00 GMTA combination of two oral drugs heals the 97% of patients with hepatitis C (16/04/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=95&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0095\2014_0095_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> A phase III clinical trial made in more than one hundred hospitals in the United States and Europe, including the Vall d’Hebron University Hospital, has shown that the combination of two antiviral drugs administered orally for 12 weeks heals patients with hepatitis C. Specifically, of the 865 patients who participated in the study, 97% were healed without suffering any major side effects. Dr. Mari Buti, researcher of the Liver Diseases Group at the Vall d’Hebron Insitute of Research (VHIR) and head of the Hepatology Section at Vall d’Hebron University Hospital, is the co-author of the research published by the online edition of the prestigious journal The New England Journal of Medicine. The traditional drugs to treat hepatitis C are interferon, which is administrated by subcutaneous injection and involves a large number of side effects such as flu symptoms and depression; and ribavirin, administrated orally and has also significant side effects such as anemia, fatigue and itching.&nbsp; Both drugs heal approximately for 70% of patients, but show a poor response in those patients previously treated with interferon and suffering liver cirrhosis. In this research, patients who had not been subjected to any of these treatments and had some degree of hepatitis C or had even developed cirrhosis, tested the effect during 12 and 14 weeks of two antiviral drugs, sofosbuvir and ledipasvir, combined in some cases with ribavirin. The trial results conclude that the most effective treating group is the combination of sofosbuvir whit ledipasvir during 12 weeks. According to Dr. Buti, this is a radical change in the treatment of hepatitis C, as "the new treatment is very well tolerated, has no significant side effects and can be used in a very wide range of patients, including those with decompensate liver cirrhosis". Thus, she adds, "the use of these drugs will reduce clearly the name of liver transplants caused by cirrhosis". Sofosbuvir is already approved in Europe and pending price in Spain, but ledispavir has not yet been filed in the registry of regulatory agencies. Both drugs will be approved as a combining form in a pill that will have to be administered daily for 12 weeks.&nbsp;&nbsp; According to the Spanish Association for the Study of the Liver (AEEH), in Spain around 900.000 people have hepatitis C<span style=" font-size: 8pt; font-family: 'Ver</td></tr></table>comunica@vhir.org (VHIR)Wed, 16 Apr 2014 00:00:00 GMTSOM Biotech develops a drug for Amyloidosis in collaboration with VHIR (15/04/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=94&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0094\2014_0094_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Vall d'Hebron Institute of Research (VHIR) and the biopharmaceutical SOM Biotech, based at the Barcelona Science Park (PCB), have signed an agreement to jointly develop the clinical phase of a drug for transthyretin Amyloidosis (ATTR). The collaboration starts with the execution of a proof of concept in 20 healthy voluntiers and patients affected by the polineuropatic form of the disease - which will confirm the efficacy and safety of compound SOM0226. The product, a repositioned drug developed by SOM Biotech, may be effective for all variants of the ATTR and has been designated recently orphan drug by the Food and Drug Administration (FDA) of United States. The Amyloidosis related to transthyretin protein is a rare disease, progressive, severe and debilitating, that mainly affects the peripheral nervous system and myocardium and, in some cases, is inherited from parents to children. The disease occurs when the liver and other parts of the body produce a mutated transthyretin protein, causing a series of aggregates that are deposited in multiple organs. This extraordinary accumulation of abnormal protein - known as deposits of amyloid - provokes local cellular damage that is expressed with a variety of clinical symptoms, leading to the death of the patient over a period of between 5 and 15 years, after suffering a major heart and nervous problems. "Currently on the world market only exists a pharmacological treatment for one of the early forms of polineuropatic transthyretin Amyloidosis.&nbsp; The cost of this treatment is very high and only has approval for Europe, so there is a clear medical need that supports the development of new drugs for the treatment of this disease", says the neurologist Dr. José Gamez, head of the research group of the Peripheral Nervous System of the VHIR and coordinator of the Neuromuscular Disease Unit at the Service of Neurology of the Hospital Universitario Vall d’Hebron, where the clinical trial will take place. </td></tr></table>comunica@vhir.org (VHIR)Tue, 15 Apr 2014 00:00:00 GMTIn search of best treatment for Chagas disease (14/04/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=93&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0093\2014_0093_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Today is the International Chagas Day, a pathology that affects between 8-10M people, causes nearly 14.000 deaths per year and is the second most prevalent tropical disease in Latin America. Dr. Israel Molina, director of the International Health Program (PROSICS) at the Catalan public institute of health (ICS) and researcher from the Infectious Diseases group headed by Dr. Albert Pahissa at Vall d’Hebron Institute of Research (VHIR), leads an international research project which aims to find a better treatment against Chagas disease. Do you know this disease and the BERENICE project? Dr. Molina explains it to us: “Chagas disease is a parasite infection caused by the Trypanosoma cruzi protozoa. Nearly 80% of the infections come from the vector called ‘vinchuca’, which is located in the clay-brick houses of Latin America. It can also be transmitted from mother to child during the pregnancy, in organ transplantations or contracted through infected food. Chagas disease is directly associated with poverty and is one of the most serious health problems in Latin America. However, due to the immigration, it also affects people in the USA and Europe. The chronic stage of this disease may cause heart complications and/or in the 20-30% of cases digestive complications. Although Chagas disease has been identified and described for more than 100 years, treatments are limited: benznidazon and nifurtimox have recurrent secondary effects, especially in adults, which lead to the interruption of the treatment in nearly the 10% of patients. The group dedicated to Tropical Medicine and International Health at Vall d’Hebron coordinates the international project BERENICE, funded by the European Commission, with the aim to obtain a drug more efficient, with improved tolerance and lower cost, whose trypanocidal activity would heal Chagas disease in endemic and non-endemic countries. <span style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-serif; font-style: normal; font-weight: normal; color: #555555; background-color: transparent; text-dec</td></tr></table>comunica@vhir.org (VHIR)Mon, 14 Apr 2014 00:00:00 GMTSend us a picture for Sant Jordi and win a tablet! (10/04/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=92&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0092\2014_0092_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Sant Jordi’s Day is coming and once again we want to see roses, dragons and books at VHIR! Send us photos or scientific pictures related to Sant Jordi and science until April 22 to comunica@vhir.org. The contest has two categories: one exclusive for VHIR's staff and the other for the rest of the society. The prize for each category is a tablet, sponsored by Pista Cero, VHIR’s supplier in IT products. On April 23 we will publish on our Facebook and Twitter profiles the pictures submitted (a maximum of 30 pictures for each category), and we will open the votes. The most voted picture in each category in the social media until April 28 at 10AM will get the prize. With this contest, we encourage VHIR researchers and staff to participate in this popular Catalan celebration and we aim to promote the excellent biomedical research that is carried out in Catalonia. Do you want to see last year’s pictures? Read the contest rules&nbsp; </td></tr></table>comunica@vhir.org (VHIR)Thu, 10 Apr 2014 00:00:00 GMTEATRIS Board of National Directors appoints a new Chair (09/04/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=91&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0091\2014_0091_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> In the bi-annual meeting held on 1st April in Amsterdam (The Netherlands), the EATRIS Board of National Directors appointed Dr. Marián Hajdúch, director of the Institute of Molecular and Translational Medicine in Olomouc (the Czech Republic) as the new Chair. The resigning Chair and director of the Vall d’Hebron Institute of Research (VHIR), Dr. Joan Comella, was re-elected as Vice-Chair. EATRIS is governed by the participating member states represented in the Board of Governors and every member state appoints a national scientific director – the national scientific directors work together and form the EATRIS’ Board of National Directors. The national scientific directors represent their country’s translational medicine institutions and are responsible for scientific coordination in their country. More than 70 prominent academic institutions are involved in the new European consortium EATRIS-ERIC, which aims to use close-knit European cooperation in order to provide the infrastructures and the know-how needed to turn the huge progress that has been made in the field of biomedical research into medical innovations with substantial benefit for patients. In Spain, VHIR coordinates together with the ISCIII this new project that will give to the participants opportunities of cross border collaboration with the aim of expediting the sharing of expertise and the faster and more efficient development of new drugs and therapies. </td></tr></table>comunica@vhir.org (VHIR)Wed, 9 Apr 2014 00:00:00 GMTHuman protein may trigger Parkinson Disease (08/04/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=88&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0088\2014_0088_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> A study led at Vall d’Hebron Institute of Research (VHIR) has demonstrated that the pathological forms of alpha-Synuclein protein extracted from patients who died with Parkinson Disease have the capacity to initiate and spread the same neurodegenerative process in mice and monkeys. The finding, published in the cover of the March issue of Annals of Neurology, may have important implications for the development of disease-modifying therapies to stop Parkinson Disease aimed at targeting expression levels, pathological conversion, and cell-to-cell transmission of alpha-Synuclein. Recent studies concluded that synthetic alpha-Synuclein forms are toxics for neurons, both in in vitro models (cell cultures) and in vivo animal models (mice), and that can be transmitted cell-to-cell. However, it was still uncertain whether the pathogenic effects of this synthetic protein may apply to the human pathological alpha-Synuclein and occur in species closer to humans. In this study, led by Dr. Miquel Vila, head of the Neurodegenerative Diseases group at Vall d’Hebron Institute of Research (VHIR) and member of CIBERNED, and with the participation of two additional groups from CIBERNED (Dr. José Obeso’s team, from the CIMA-Universidad de Navarra, and Dr. Isabel Fariñas’ Team, from the Universitat de València), and a group from the Université de Bordeaux  in France (Dr. Erwan Bezard) , researchers extracted alpha-Synuclein aggregates from patients who died with Parkinson Disease to inoculate them in the brain of mice and monkeys. Four months after the inoculation in mice and nine months later in monkeys, the animals started the neurodegenerative process, starting at striatal dopaminergic terminals. With these results, Dr. Vila concludes that “human pathological alpha-Synuclein aggregates trigger in mice and monkeys the same neurodegeneration process than Parkinson Disease”. </td></tr></table>comunica@vhir.org (VHIR)Tue, 8 Apr 2014 00:00:00 GMTAnaphylaxis, when allergies can be severe and fatal (07/04/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=87&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The World Allergy Week, organized by the World Allergy Organization and the European Academy of Allergy and Clinical Immunology, began today and will run through April 13, with the slogan 'Anaphylaxis, when allergies can be severe and fatal'. The aim of this year’s campaign is to increase awareness of the symptoms and the treatment of anaphylaxis, which is a pathology that can be fatal if it is not detected quickly and properly.   According to Dr. Victòria Cardona, responsible of the Allergy Section at Vall d’Hebron University Hospital, researcher of the Systemic Diseases group at Vall d’Hebron Institute of Research (VHIR) and secretary of the Spanish Society of Allergy and Clinical Immunology, “the objectives of the campaign are to stress the importance of anaphylaxis, to provide information about the increased prevalence, and to improve the education and the patient services in order to improve the security and quality of life of patients”.   Food, drugs and hymenoptera bites (wasps and bees) are the most common causes of anaphylaxis. For that reason, “it is very important that people affected, their families, professionals and friends must be able to quickly diagnose and start the treatment as soon as possible”, reports the allergist.   Dr. Cardona leads two research lines in the Allergy Laboratory at VHIR: the first one aims to find useful biomarkers to diagnose anaphylaxis, and the second to study the role of cofactors such as alcohol, stress, anti-inflammatory drugs and exercise, in the disease. Dr. Mar Guilarte, researcher from the same lab, explains the research lines in the video attached.   It is estimated that anaphylaxis will affect 1 out of 300 people at some time in their lives. Besides, a study led by the Hospital de Alcorcón demonstrates that the prevalence of anaphylaxis increased between 2005 and 2011, so that it is a medical emergency with increased incidence.   <p style=" text-align: left; text-indent: 0px;</td></tr></table>comunica@vhir.org (VHIR)Mon, 7 Apr 2014 00:00:00 GMTCreativity takes over 2nd Science Beer (03/04/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=86&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The protagonists: two medical researchers, an artist, and a journalist as the moderator. Do you want to know them? The topic: the creativity that leads them to finding a needle in a haystack. The place: a reserved floor at The Velodrome bar in Barcelona, where there was no lack of Moritz Beer.&nbsp; Here's the video with the summary of the 2nd Scientific Beer! </td></tr></table>comunica@vhir.org (VHIR)Thu, 3 Apr 2014 00:00:00 GMTThe Catalan Society of Neurology awards Dr. José Álvarez Sabín for his professional and academic career (01/04/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=85&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0085\2014_0085_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Catalan Society of Neurology and the Catalan Academy of Medical Sciences have awarded with the E. Beltran Rubio prize Dr. José Álvarez Sabín, head of the Neurology Service at Vall d’Hebron University Hospital and researcher of the Neurovascular Diseases group at Vall d’Hebron Institute of Research (VHIR). Both entities have recognized his professional and academic career in the field of vascular and cerebral pathologies. For Dr. Álvarez Sabín, the prize “is an acknowledgement of the hard work that I have been indeed fortunate to develop in the best period of neurology, in an outstanding international country, and it gives me strength to continue to go forward”. The Catalan Society of Neurology has also awarded with the Antoni Subirana Prize the former presidents of the entity, Dr. Oriol de Fàbregues, researcher of the Neurodegenerative Diseases group at VHIR and responsible of the Parkinson’s Disease Unit at the hospital, Dr. Mercè Boada, former head of the Dementia Unit and the Alzheimer’s Disease research group at VHIR, Dr. Manel Roig, researcher of the Pediatric Neurology group at VHIR and former head of the Neuropediatric Service, and doctors Nolasc Acarin, Feliu Titus and Agustí Codina, former responsible of the Neurology Section, the Headache section and the Neurology Service. In the ceremony awards, hosted in Sitges the March 20, was also recognized La Marató de TV3 Foundation for its dissemination activities in neurological diseases, and its commitment to collect funds for the research in these path</td></tr></table>comunica@vhir.org (VHIR)Tue, 1 Apr 2014 00:00:00 GMTWorld Colon Cancer Day (31/03/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=83&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0083\2014_0083_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Coinciding with the World Colon Cancer Day, Dr. Diego Arango, head of the Molecular Oncology group at CIBBIM-Nanomedicine at Vall d’Hebron Institute of Research (VHIR), talks about the prevention and the state of research in this disease: Today, on March 31, is the colorectal cancer awareness day. This disease affects nearly 450,000 Europeans, causes more than 210,000 deaths per year, and it is the type of cancer with the highest incidence throughout the western world.&nbsp; Fortunately, more than the 90% of the cases can be cured if are detected in the early stages. In this international day against colorectal cancer, we want to draw the attention in the prevention and the early detection. To reduce the risk of suffering this disease it is important to: Follow a balanced diet, low in saturated fat and rich in fiber (cereals, legumes, etc.), and eat fruits and vegetables daily. Practice exercise and maintain a healthy weight. Don’t smoking. For the early detection of the disease, it is important to be aware of the changes in the bowel function that last several weeks and to detect the possible presence of blood in the feces. Besides, from the age of 50 it is recommended to take a test regularly to detect the presence of hidden blood in the feces, or to get a colonoscopy. These tests should be taken first in people with high risk of suffering colorectal cancer; this is the case of the people with inflammatory bowel diseases and relatives (parents, siblings or descendants) with colon cancer. The Molecular Oncology group at CIBBIM/VHIR investigates the molecular causes that lead to the disease. Our group is interested in studying the role of several genes that we think that are important for the progression of this type of tumors. We also investigate new personalized treatments with chemotherapy for patients with colorectal cancer, in order to improve the evolution of the disease. Dr. Diego Arango leads an international project<span style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-s</td></tr></table>comunica@vhir.org (VHIR)Mon, 31 Mar 2014 00:00:00 GMTWoman with severe congenital heart disease gives birth thanks to a pioneer surgery during the pregnancy (31/03/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=84&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0084\2014_0084_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> A multidisciplinary team from Vall d’Hebron University Hospital, coordinated by Dr. David García Dorado, head of the Cardiocirculatory Pathology group, conducted a surgery on a 22 weeks’ pregnant woman, who was wearing a prosthesis that replaced the aortic valve. The prosthesis failed by the stress of the heart during the pregnancy, and consequently, she suffered heart failure and a severe stenosis that put her life and the fetus’ life at risk. The impaired heart function of the woman, who was born with a severe congenital heart disease, and the high risk of losing the fetus in a surgical operation (30%), the medical team led a pioneer technique, known as valve in valve. It consists in the implementation of an aortic prosthesis inside the prosthesis that she was already wearing, in order to repair it.&nbsp; The second prosthesis was implanted using minimally invasive techniques, through the introduction of a catheter into one of her femoral arteries, until arriving to the prosthesis that failed. The baby was born in January, in the 37 week of pregnancy. Both mother and child are healthy. It is the first time that this procedure is used in a pregnant woman. </td></tr></table>comunica@vhir.org (VHIR)Mon, 31 Mar 2014 00:00:00 GMTDr. Guarner leads the World Digestive Health Day campaign (28/03/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=82&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0082\2014_0082_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Francisco Guarner, researcher from the Physiology and Pathophysiology of the Digestive Tract group at Vall d’Hebron Institute of Research (VHIR), is the chair of this year’s World Digestive Health Day, organized by the World Gastroenterology Organization, the May 29. The aim of the campaign is to raise awareness of the benefits and risks that the bacteria that inhabit the human gut have in our health. The digestive tract harbors a huge ecosystem of microbial communities that play key roles in digestion, metabolism and immune functions. In fact, Dr. Guarner assures that “changes in the diversity and function of those communities are associated with far reaching consequences on host health and have been linked with a number of disorders, including functional bowel disorders, inflammatory bowel diseases and other immune mediated diseases, such as celiac disease and allergies; metabolic conditions, like type 2 diabetes and NASH; and perhaps, behavioral disorders such as autism and depression”. Dr. Guarner participated at the Gut Microbiota for Health World Summit in Miami (USA), on March 8-9, coordinating a workshop on prebiotics and probiotics. In a video interview recorded at the same congress, he explained the importance of preserving the gut microbiota diversity lifelong. He also participated in the IX International Congress on Nutrition, Food and Diet, hosted in Madrid from the 19 to the 21 of March, with a lecture about the role of gut microbiota in the metabolic regulation of obesity. </td></tr></table>comunica@vhir.org (VHIR)Fri, 28 Mar 2014 00:00:00 GMTDr. Anna Meseguer wins the 2nd prize of the VALORTEC contest of patents (27/03/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=81&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0081\2014_0081_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Anna Meseguer, head of Kidney Physiopathology group from CBBIM-Nanomedicine at Vall d’Hebron Institute of Research (VHIR), won the 2nd prize of the 3rd edition of the VALORTEC contest, in the category of patents’ business plan, organized by ACCIÓ. The project, awarded with 2,000 euros, has a European patent to develop a method of diagnosis and prognosis of Clear Cell Renal Carcinoma (ccRCC). The ccRCC is the most common and aggressive type of renal cancer. It doesn’t show any signs, symptoms or biochemical anomalies for detecting the tumor, so that in the 30% of cases is detected incidentally too late, with a complementary test. In a first study published in the European Journal of Cancer, the team led by Dr. Meseguer detected that the levels in the urine of a membrane protein of renal cells, called HAVCR-1/KIM1, were connected with the degree and the malignancy of the tumors of ccRCC. This finding presented an innovative diagnosis method alternative to the invasive biopsies. Then, in a further study published recently in Cancer Research, VHIR researchers discovered that HAVRC/KIM-1 controls important genes for the growth and the progression of the tumor. Researchers are now valorizing a European patent, validating pSTAT-3 Ser727 as a biomarker of survival to ccRCC in a second independent cohort of 125 patients, with 5 years of follow-up. They are also designing a new software to automatically quantify the biomarker and then develop the diagnostic kit. Another project of Vall d’Hebron is one of the finalists</td></tr></table>comunica@vhir.org (VHIR)Thu, 27 Mar 2014 00:00:00 GMTVHIR launches a series of conferences on rare diseases (24/03/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=77&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0077\2014_0077_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> On April 1st, started the first series of conferences on rare diseases organized by Vall d’Hebron Institute of Research (VHIR), with the lecture of Dr. Manuel Posada, director of the rare diseases institute at Instituto de Salud Carlos III. The Fundación Areces sponsors 8 out of the 12 seminars that will take place in Barcelona and Madrid, coinciding with the 20th anniversary of the Institute. The first lecturer who visited Vall d’Hebron talked about rare diseases registries which are basic data tools to foster research and improving the medical attention to these patients. The seminar took place at the lecture room located in the ground floor of the General Area of the Vall d’Hebron University Hospital; the same room that will host during the following weeks the seminars of Dr. Ignacio Burgos, driver and coordinator of the rare diseases workshop at the Senate, Dr. Francesc Palau, scientific director of the Spanish network on rare diseases (CIBERER), and Juan Carrión, president of the Spanish alliance of rare diseases. The seminars with the support of Fundación Areces will take place in their auditorium located in Madrid, and in the 10th floor of Vall d’Hebron hospital. The first seminar will be conducted on April 30th at Vall d’Hebron by Dr. Alastair Kent, director at the Genetic Alliance UK that is the British charity of 150 patient organizations, supporting all those affected by genetic conditions. The other lecturers that will participate in the VHIR-Fundación Areces seminars are Dr. Christoph Klein, Physician-in-Chief and Chairman at the Dr. von Hauner Children’s Hospital in Munich (Germany), Dr. Paul Lasko, Scientific Director at the Institute of Genetics of the Canadian Institutes of Health Research, Prof. Danilo Tagle, program director for Neurogenetics at the National Institute of Neurological Disorders and Stroke at the University of Michigan (USA), <a style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-serif; font-style: normal; font-weight: bold; color: #8c2b90; background-color: transparent; text-decoration: none;" href="http://www.vhir.org/activitats/relacioactivitats_detall.asp?</td></tr></table>comunica@vhir.org (VHIR)Mon, 24 Mar 2014 00:00:00 GMTUNNIN's researchers have organized a workshop on traffic accidents and traumatic brain injury (20/03/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=76&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0076\2014_0076_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Coinciding with the Brain Awareness week and for the fifth consecutive year, professionals from Vall d’Hebron and researchers of the Neurotraumatology and Neurosurgery Research Unit (UNINN) at VHIR, organized the workshop ‘Viu de prop el problema: coneix les causes i parla amb el malalt. Accidents de trànsit i traumatismes cranials. Causes i conseqüències', about the traumatic brain consequences that people can suffer after surviving a traffic accident. High school students from the IES Consell de Cent talked with doctors, researchers and patients about what is considered as the silent epidemic of XXI century and the first cause of death among young people: traumatic brain injuries caused by traffic accidents. The students also heard the experience of the president of the Catalan Association of Traumatic Brain Injury Affected, who suffered an accident when she was 17, as well as they visited the patients hospitalized in the intensive care unit and learned how professionals act when a patient with a traumatic brain injury arrives to the hospital. Vall d’Hebron is the reference in Catalonia in the integral treatment to patients with multiple traumas, trough the Polytrauma Code, a system of coordination and communication between the different levels of health care attention to patients who suffer multiple traumas. </td></tr></table>comunica@vhir.org (VHIR)Thu, 20 Mar 2014 00:00:00 GMTDiabetes treatments don't increase the risk of cancer (19/03/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=75&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0075\2014_0075_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Researchers from Vall d’Hebron Institute of Research (VHIR), led by Dr. Rafael Simó, head of the Diabetes and Metabolism group, have demonstrated that the glucose-lowering drugs used for the treatment of Diabetes type 2 don't increase the risk of developing cancer. In the study, published in PLOS ONE, also participated 16 Primary Health Care centers of Barcelona, the IDIAP Jordi Gol and the Oncology Service at Vall d’Hebron University Hospital. Patients with type 2 diabetes have a greater risk of suffering from three of the leading causes of cancer mortality such as pancreatic, colorectal and breast cancer. Despite both diseases have common risk factors including age, race, ethnicity, obesity, physical inactivity, and tobacco use, the causes of this link are still unknown. The aim of VHIR researchers was to evaluate the impact of glucose-lowering agents in the risk of cancer in a large type 2 diabetic population. More than 275.000 type 2 diabetic patients older than 40 years registered in the SIDIAP (Sistema d’Informació per al Desenvolpament de la Investigació en Atenció Primària) and attending 16 Primary Health Care Centers of Barcelona were studied. From the cohort, they selected 1.040 cases of type 2 diabetes diagnosed with cancer between 2008 and 2010 and registered at the Cancer Registry of Vall d’Hebron University Hospital, which collects data about the diagnosis date, the tumor location and the pathological characteristics. This group of patients was compared with 3.120 case control patients with type 2 diabetes and without cancer. Regarding the treatments, researchers analyzed the different types of insulins and the oral antidiabetic drugs administered to the patients during the previous three years to the cancer diagnosis. <span st</td></tr></table>comunica@vhir.org (VHIR)Wed, 19 Mar 2014 00:00:00 GMTIdentified the mechanism of action of a key protein in the protection from cell death (17/03/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=73&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0073\2014_0073_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Researchers from the Cell Signaling and Apoptosis group at Vall d’Hebron Institute of Research (VHIR), led by Dr. Joan Comella, have discovered that a neuronal protein, the long isoform of FAIM-L (Fas Apoptotic Inhibitory Molecule) protects from apoptosis or programmed cell death, by regulating one of the Inhibitor of Apoptosis Proteins, called XIAP. The groundbreaking research has been published in The Journal of Neuroscience. Apoptosis is a physiological process that regulates the number of cells in the body, by eliminating those that are overexpressed, injured, or have transient functions. It plays an important role in neurodegenerative diseases, because its overexpression causes cell death, as well as in cancer, because its inhibition triggers the tumor progression. XIAPs are the most potent caspase inhibitor in vitro and their levels are decreased in neurodegenerative diseases such as Alzheimer’s disease. In this study, VHIR researchers discovered the link of these inhibitors with the neuronal protein FAIM-L, which was previously reported as a protector from neuronal death. Specifically, they have identified in mice that FAIM-L protects the degradation of XIAP, impeding the apoptosis activation and then, allowing the neuronal survival. With this results, Dr. Comella expects that “the use of FAIM-L as an XIAP ‘guardian’ might not be restricted to the nervous system and deserves to be exploted in other systems with deleterious cell death, such as auto-immune diseases”. Dr. Rana S. Moubaraq, who is currently working at the Skirball Institute of Biomolecular Medicine in New York, is the first author of this study that opens the door to further research in new drugs against neurodegenerative diseases. </td></tr></table>comunica@vhir.org (VHIR)Mon, 17 Mar 2014 00:00:00 GMTThe Catalan Diabetes Association awards a project on diabetic retinopathy carried out at VHIR (14/03/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=69&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0069\2014_0069_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Diabetes and Metabolism group, led by Dr. Rafael Simó at Vall d’Hebron Institute of Research (VHIR), has been awarded with the 2014 grant of the Catalan Diabetes Association, for the project “Neuroprotection by GLP-1: preclinical development of a new therapeutic strategy for diabetic retinopathy”. The study aims to administer in mice with the diabetes murine model a neuroprotective eye drops drug, the GLP-1, to assess if the diabetes’ early retinal damage can be prevented. The study will start in the next weeks and the outcomes will be published next year. The Catalan Diabetes Association concedes the 10,000€ grant with the objective to support the development of clinical research projects that improve the knowledge of the disease and the medical attention to patients.&nbsp; </td></tr></table>comunica@vhir.org (VHIR)Fri, 14 Mar 2014 00:00:00 GMTDr. Daniel Seron talks about research in kidney failure (13/03/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=68&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0068\2014_0068_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Coinciding with the World Kidney Day, Dr. Daniel Seron, head of the Nephrology group at Vall d’Hebron Institute of Research (VHIR), and responsible of the Nephrology Service in the hospital, talks about the state of research in kidney failure: “Approximately 10% of the population suffers any kind of kidney failure, including the asymptomatic mild forms and the severe forms which require either dialysis or transplantation. There is a close relationship between cardiovascular and kidney diseases. Patients with kidney failure have a higher risk of suffering from myocardial infarction or stroke, and the common risk factors for cardiovascular diseases, such as elderly, smoking, hypertension, diabetes and obesity, increase the risk of suffering from kidney failure. Thus, prevention measures for cardiovascular diseases are efficient to reduce the probability of suffering from this disease. For that reason, the Nephrology Service of the Vall d’Hebron University Hospital investigates the relationship between both diseases, in patients with chronic renal disease and transplanted patients. One of our research lines is the characterization, in different groups of patients, of the role of the endothelial activation, the low-grade inflammation and the endothelial regenerative capacity in cardiovascular diseases. Another point of interest is the assessment of preventive measures to impede the course of the renal disease and its consequences on the cardiovascular disease. On the other side, another of our successful strategies to reduce the cardiovascular risk of patients with kidney failure undergoing hemodialysis is the kidney transplantation. For this reason, the Service has incorporated different strategies to increase the chances for transplant for the patients who are in the waiting list, such as the definition of the criteria for using kidneys from elderly patients, the promotion of living-related transplants or the horseshoe kidney transplants. Finally, it is important to mention that in the last couple of years has increased the interest in the development of new drugs to slow the progression of the kidney injury in different common diseases, such as the diabetic nephropathy. These advances represent a great hope for the research in solutions for patients with kidney failure, and the Nephrology Service actively participates in different clinical trials to evaluate the efficacy of these new treatments”. </td></tr></table>comunica@vhir.org (VHIR)Thu, 13 Mar 2014 00:00:00 GMTNew treatment improves survival for advanced cervical cancer (12/03/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=64&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0064\2014_0064_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Vall d’Hebron University Hospital has participated in an international study, published in the New England Journal of Medicine, which has demonstrated that the addition of bevacizumab to combination chemotherapy in patients with recurrent, persistent or metastatic cervical cancer improves the overall survival and reduces by 30% the risk of dying from this disease. The hospital and the Vall d’Hebron Institute of Oncology are, together with other Spanish Centers from the GEICO (the Spanish network of research in ovarian Cancer), the only European participants of the international phase III clinical trial which has used a combination of chemotherapy and bevacizumab, which is an antibody administered to manage cancer because it inhibits the tumor growth and prevents the formation of new blood vessels from the preexisting ones. Up to date, when the initial treatment failed in these patients (surgery in early stages and a combination of chemotherapy and radiotherapy for advanced stages), the only therapeutic option was the conventional chemotherapy, which had an overall survival of one year. The study was carried out in 452 patients with cervical cancer from 164 American and Spanish hospitals. All the patients had previously received the standard treatment, but the cancer remained or had just reappeared. With the combination of bevacizumab and chemotherapy, the average survival improved in nearly 4 months and reduced by the 30% the risk of dying from this cancer. Dr. Ana Oaknin, oncologist specialized in gynecology tumors at Vall d’Hebron, explained that “before the beginning of the clinical trial in 2009, it was very difficult that these patients could live more than one year, but now their survival has improved to the 17 months, preserving their quality of life”. “It seems a little step, but it is very important because this cancer mainly affects young women, aged between 30 and 40, who use to have a strong family environment”, reported Dr. Oaknin. Vall d’Hebron University Hospital treats every year nearly 25 women with advanced cervical cancer, and is the reference center in Spain for this disease.&nbsp; </td></tr></table>comunica@vhir.org (VHIR)Wed, 12 Mar 2014 00:00:00 GMTThe SEIP awards a Dr. Pere Soler-Palacín's project on pediatric osteomyelitis (12/03/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=67&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0067\2014_0067_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Pere Soler-Palacín, researcher from Infection in Immunocompromised Pediatric Patients group at Vall d’Hebron Institute of Research (VHIR) and doctor from the Infectious Pathology and Pediatrics Immunodeficiencies Unit at Vall d’Hebron University Hospital, has been awarded with 6,000 euros by the Spanish Society of Pediatric Infections for the project “Antibiotic bone penetration into bone infections in immature skeletons. Pharmacokinetics study in animals”. The project aims to assess the penetration of antibiotics in both healthy and infected bones from rabbits, in order to combat osteomyelitis. This infection is quite common among children and carries a significant risk of permanent motor sequels. According to Dr. Soler-Palacín, the study is important because “there is no pharmacokinetic evidence to validate the use of the recommended antibiotics to manage acute hematogenous osteomyelitis in children, taking into account the bone penetration of the different ways of administration and its association with the age of patients”. If the results confirm his hypotheses, the hospital admission could be reduced because of the reduction in the duration of the antibiotic treatment by intravenous route. The study started in the second semester of 2013, thanks to another grant by the Catalan Society of Traumatology and Orthopedic Surgery and is a joint project of the Infection in Immunocompromised Pediatric Patients group, the Neuromuscular and Mitochondrial Pathology group, the Microbiology group, and the Bioengineering, Orthopedics and Surgery in Pediatrics group. The total budget of the research is 63,400 euros and the outcomes will arrive the second semester of 2015. </td></tr></table>comunica@vhir.org (VHIR)Wed, 12 Mar 2014 00:00:00 GMTThe Health Care research group publishes in 'The Lancet' a study on nurses' workload (11/03/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=63&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0063\2014_0063_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Carmen Fuentelsaz, head of the Health Research group at Vall d'Hebron Institute of Research (VHIR), has led in Spain, together with Dr. María Teresa Moreno, researcher from the Instituto de Salud Carlos III, a European study on nurses' workload and education, published in the prestigious journal The Lancet. The study findings, derived from more than 420.000 patients in 300 hospitals across nine European countries, among them Vall d’Hebron University Hospital, indicate that patients are more likely to die after common surgical procedures when they are cared for in hospitals with heavier nurse workloads and fewer nurses with bachelor’s degrees. </td></tr></table>comunica@vhir.org (VHIR)Tue, 11 Mar 2014 00:00:00 GMTFinding a needle in a haystack, second VHIR’s Science Beer (10/03/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=62&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0062\2014_0062_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> After launching the first Science Beer of Vall d' Hebron Institute of Research (VHIR), one of the activities that the Institute has prepared for the celebration of its 20th anniversary, we invite you to attend the second Science Beer. This new talk format is based on interdisciplinary dialogue of any current scientific issues among recognized experts of three different but complementary areas. With an dynamism, plain language and an informal tone , the moderator will introduce briefly some ideas for the guest speakers to debate. The audience will then be invited to join the conversation with questions and open direct discussions with the guests, thus allowing closeness between them and enjoying the privilege to have first rate experts to satisfy their queries. Science Beer opens the door to an innovative format in citizen’s science, and is organized by VHIR’s Development Unit with the collaboration of Cervezas Moritz and TheDoctorFactory. Second VHIR’s Science Beer The second Science Beer is titled Finding a needle in a haystack and aims to generate a debate on the passion to discover new ways of watching, from the point of view of an artist and a researcher: which features are shared, how does infinite curiosity pushes to go further, and a long list of exciting questions that will cross-over amongst the audience, the moderator and the guests: Ferran Morell, head of VHIR’s Pneumology Research Group and Chief of Pneumology Service at HUVH Francisco Guarner<span style=" font-size: 8pt; font</td></tr></table>comunica@vhir.org (VHIR)Mon, 10 Mar 2014 00:00:00 GMTFrom predoc to group leader, 4 stories of women working at VHIR (07/03/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=61&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0061\2014_0061_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Coinciding with the International Women’s Day, we have interviewed 4 researchers working at different levels of the scientific career at Vall d’Hebron Institute of Research (VHIR), in order to get their experiences in this sector that, according to the latest study published by the UNESCO, it is still a men’s issue: the worldwide average of women in science is the 30%, whereas the average in Spain is a little bit higher, the 38%. Nonetheless, the statistics are completely different at VHIR, where the 75% of researchers are women! Matilde Lleonart, leader of the Oncology and Molecular Pathology group. 43 years old. “I think that we have been cheated with the concept of the working women. It is very difficult to combine this stressful career with children! We have a lot of pressure to publish and when we don’t get the results expected, all the effort and the time spent in research seem useless. For that reason and in my case, I think that the support of your partner is crucial to do this job. Now I’m 7 months pregnant and I already know that the First of September I will have to be in the lab, because the maternity leave is clearly insufficient in Spain. However, I will also be working because I have a moral commitment with science and with my master and predoctoral students, as well as the postdoctorals, and I cannot leave my group without a leader. To get where I am today, I reckon that sometimes I had to work more than my male colleagues, and at the beginning, when I was doing the PhD, there was also an economic gender gap in my level in Spain and other international centers. Nonetheless, now I’m happy because do what I want and I use to forgot all the suffering and the effort when a paper from my group is published. Thus, I encourage all women to use our moral strength because we can get whatever we want!” Marta Ribases, Miguel Servet researcher from the Psychiatry, Mental Health and Addictions group. 36 years old “I have had to children and I worked until the last day of the pregnancy in both cases, and my scientific performance didn’t stop. My research is much related to Bioinformatics and Biostatistics, so I can combine easily professional and family life, working from home. However, we sometimes have to struggle (both men and women) to combine our family life with this</td></tr></table>comunica@vhir.org (VHIR)Fri, 7 Mar 2014 00:00:00 GMTA study discovers that Reelin protein rescues cognitive deficits in an animal model of Alzheimer's disease (06/03/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=59&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0059\2014_0059_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Reelin, a crucial protein for adult brain plasticity, recovers cognitive functions in mice with Alzheimer’s disease. This is one of the main results of an article published on the journal Nature Communications, co-led by Eduardo Soriano, researcher from Vall d'Hebron Institute of Research professor from the Department of Cell Biology at the University of Barcelona (UB) and member of the Centre for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED), and researcher Lluís Pujadas (UB and CIBERNED). The study is part of the PhD thesis developed by Daniela Rossi, co-author of the article together with Lluís Pujadas. Natàlia Carulla, from the Institute for Research in Biomedicine (IRB), collaborated actively in the research too. Other participants are: M. Rosa Andrés, Cátia M. Teixeira, Antoni Parcerisas, Ernest Giralt, Bernat Serra and Rafael Maldonado, and the institutions Research Center for Neurological Diseases Foundation (CIEN Foundation) and Pompeu Fabra University (UPF). To recover cognitive functions in models of Alzheimer’s disease Alzheimer’s disease is a neurodegenerative disease characterised by progressive cognitive deficits, synaptic loss and neuronal death. It is mainly associated with the formation of senile plaques (extracellular deposits of amyloid-ß, Aß) and the presence of neurofibrillary tangles (intracellular bundles of tau protein). The disease, which is the most common form of dementia in the elderly, affects more than 100,000 people in Catalonia and 500,000 in Spain, and causes progressive degeneration of patients’ intellectual and cognitive functions. This new preclinical study proves that an increase in Reelin brain levels avoids cognitive deterioration in mouse models of Alzheimer’s disease. Moreover, Reelin delays amyloid-beta fibril formation in vitro and reduces amyloid deposits in mice with Alzheimer’s. The double pathway of Aß peptide and tau protein Professor Eduardo Soriano, head of the Research Group Developmental Neurobiology and Neuroregeneration of UB, explains that “most studies on Alzheimer’s disease search for therapeutic targets addressed to a certain process involved in the disease”. On the contrary, “our study analyses the signalling pathway of Reelin—a synaptic and cognitive enhancer— that regulates the amyloid precursor protein (APP) and tau protein, which are both involved in basic processes of Alzheimer’s disease”. Lluís Pujadas, first author of the article together with Daniela Rossi, points out: “We knew that Reelin is involved in the double regulating pathway</td></tr></table>comunica@vhir.org (VHIR)Thu, 6 Mar 2014 00:00:00 GMTDr. Fátima Núñez presents EATRIS at the VII Annual Conference of the Biomedical Research Technological Platforms (05/03/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=58&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0058\2014_0058_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Fátima Núñez, director of the Technical &amp; Scientific Support Area at Vall d’Hebron Institute of Research (VHIR), presented the new European biomedical translational research infrastructure, EATRIS-ERIC, at the VII Annual Conference of the Biomedical Research Technological Platforms, held in Barcelona the 4 and 5 of March. More than 70 prominent academic institutions are involved in the new European consortium EATRIS-ERIC, which aims to use close-knit European cooperation in order to provide the infrastructures and the know-how needed to turn the huge progress that has been made in the field of biomedical research into medical innovations with substantial benefit for patients. In Spain, VHIR coordinates together with the ISCIII this new project that will give to the participants opportunities of cross border collaboration with the aim of expediting the sharing of expertise and the faster and more efficient development of new drugs and therapies. The conference was focused on the new European programme of research, Horizon 2020, and the national and international projects that facilitate the cooperation of all public and private actors that have been promoted from the Biomedical Research Platform. </td></tr></table>comunica@vhir.org (VHIR)Wed, 5 Mar 2014 00:00:00 GMTA study by the Digestive Transplants Group receives the prize to the Best Article about Transplants 2014 (04/03/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=57&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0057\2014_0057_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Catalan Transplantation Society and the Royal Academy of Medicine of Catalonia have awarded Dr. Gonzalo Sapisochin, researcher of the Digestive Transplants Group at Vall d’Hebron Research Institute (VHIR), with the prize to the Best Article about Transplants 2014, for the study "Single HCC in cirrhotic patients: liver resection or liver transplantation? Long-term outcome according to an intention-to-treat basis", published in the&nbsp; Annals of Surgical Oncology in April 2013. The VHIR researchers, lead by Dr. Ramon Charco as the Group Head, conducted a retrospective study with ten years follow-up of more than 200 patients with hepatocellular carcinoma treated at the Vall d’Hebron University Hospital between 1997 and 2007. The aim of the study was to determine, for the first time, which of the two treatments made in these patients had the best long-term results according to the treatment intention: the liver transplant or the liver resection. With the results obtained, the researchers concluded that the liver resection is the most recommended treatment for patients in the earliest stages of liver cancer, with a tumor equal or smaller than two centimeters, while the liver transplant is the best treatment option for patients in the early stages, with a tumor equal or smaller that five centimeters, if and when they meet the other requirements to be transplanted. The prize is endowed with 2.000€ and the Academic Correspondent Title of the Royal Academy of Medicine of Catalonia. The award ceremony will take place on May 6th. </td></tr></table>comunica@vhir.org (VHIR)Tue, 4 Mar 2014 00:00:00 GMTVHIR signs an agreement with the Institute of Molecular and Translational Medicine (03/03/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=55&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0055\2014_0055_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Vall d’Hebron Institute of Research (VHIR) has recently signed a collaboration framework agreement with the Institute of Molecular and Translational Medicine (IMTM), located in Olomouc (Czech Republic), as a part of the actual UAT policy devoted to establish new collaborations with third-parties in order to expand its services portfolio. Through this agreement, VHIR and IMTM are now able to share scientific and technical platforms, allowing VHIR researchers to access the amazing IMTM facilities in a collaborative manner. Also, PhD students from both institutions will benefit from the agreement, since they will be able to spend part of their PhD in the other centre through a shared PhD training program. IMTM is a recently inaugurated translational research centre and is considered one of the most influential research projects carried out in the Czech Republic. It is dedicated to basic and translational biomedical research and encompasses an impressive technological infrastructure including high-throughput platforms with unique technologies. These platforms include Bioinformatics and Biostatistics, Animal Models, Genomics, Proteomics and Cell Biology Core Facilities. The 'star' facility is an impressive high-throughput-screening and high-content-analysis (HTS/HCA) platform, one of the largest academic installations worldwide, based on state-of-the-art robotics and equipped with automatic incubators, liquid handlers for ìl and nl volumes and readers for fluorescence, luminescence, absorbance and ionizing radiation. Wide-field and spinning disk confocal microscopes equipped with specialized image analysis softwares are also included. Crucial part of the robotic system is the automated chemical library, which contains more than 120.000 compounds suitable for a variety of tests. For VHIR’s director, Dr. Joan Comella, this type of agreements between leading international translational institutions seek to promote the use of the most advanced technological tools to further translational research and offers the opportunity of excellent training for our promising young talent. Through international collaborations like this one, he emphasises that “we become more competitive and stronger because this is undoubtedly the way scientific discoveries and innovation advance, and how our research can be translated into applied answers to societal health challenges that can reach society faster and more efficiently”. </td></tr></table>comunica@vhir.org (VHIR)Mon, 3 Mar 2014 00:00:00 GMTListen to Didac’s parents, whose son suffers a rare disease (28/02/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=53&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Coinciding with the Rare Disease Day, here is the testimony of Didac’s parents, whose two-year-old son was born with a Primary Immune Deficiency (PID), a rare disease caused by alterations in the immune system. During the last couple of months, the family raised over 10,000 euros to encourage research at Vall d’Hebron Institute of Research (VHIR) in this disease that caused the death of Juan, Didac’s Elder brother. As his father reports, “these diseases are not rare because they are more difficult to heal, but because in research there isn’t enough time to study them”. According to the Spanish association of rare diseases, nearly 3 million people in Spain suffer one of the 7,000 rare diseases registered in the country. Nearly 200 of them are being investigated at VHIR, with a funding over 10M euros, and more than 200 clinical trials in this field have been conducted in the last 4 years. Research in rare diseases is a priority for VHIR and that’s why the Institute will organize this year, together with Fundación Areces, a specialized seminar series on these diseases. On Sunday 2, VHIR will also participate in the <a style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-serif; font-style: normal; font-weight: normal; color: #8c2b90; background-color: transparent; text-decoration: underline;" href="http://www.rtve.es/television/20140227/emotividad-sorpresas-gran-espectaculo-telemaraton-investigacion-en</td></tr></table>comunica@vhir.org (VHIR)Fri, 28 Feb 2014 00:00:00 GMTThe Science Beer achieves its eight-thousand (28/02/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=54&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0054\2014_0054_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> “Our eight-thousander has to be to transform society”. With this and many other deep thoughts, the guests of the first Scientific Beer organized by the Vall d' Hebron Research Institute ( VHIR ) spoke, in an exciting, intense, deep, thoughtful, humane and passionate way, about their three visions of the challenges every day have to overcome to achieve the highest peak, not only as scientists and mountaineer, but also as parents, and, above all, as people. In an intimate and informal atmosphere, Joan Montaner, Head of Neurovascular Diseases Group at&nbsp; VHIR, Mara Dierssen, Head of Research &amp; Systems Neurobiology Cellulars Group at the Centre for Genomic Regulation (CRG ) and President of the Spanish Society for Neuroscience, and Ferran Latorre, alpinist who has made ten eight-thousanders, reflected on concepts that go beyond their personal challenges and connect with the self worth of life and people . "When you discover something new you feel an indescribable feeling, but you can’t stop there, you have to enjoy and appreciate the path that has led you there", shared Joan Montaner. Attendees talked about concepts such as curiosity, enjoying the journey and not just the goal, passion as the engine of any challenge that we want to beat, and the value of humility above all, as Ferran Latorre said: "The failures I've had have given me humility". Words that provoked a reaction of emotion in the audience, the other main focus, which was very focused in all that was happening from the stage of the Teatret dels Lluïssos de Gràcia. Precisely the public was the driver of the second part of the conversation through questions and reflections made to the guests. Probably learned from their own experiences, as it was inevitable not to feel absolutely identified with many of the ideas that resonated between the seats. All these detached emotions were captured in situ by the painter Trinidad Sotos Bayarri, mother of Mara Dierssen, drawing in live with an iPad. To finish off this sensory experience, Mara Dierssen took the microphone and thrilled the audience with a concert of his music group FromLosttotheRiver, one of his many eight-thousanders. Take a look at the drawings here! </td></tr></table>comunica@vhir.org (VHIR)Fri, 28 Feb 2014 00:00:00 GMTA Mobile app could simulate the effect of a drug in the human body to support the clinical decision (27/02/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=52&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0052\2014_0052_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Coinciding with the Mobile World Congress in Barcelona, the Catalan Biotech Anaxomics presented, together with Vall d’Hebron Institute of Research (VHIR), the launching of CrossAN, a project that will use systems biology to select personalized treatments for renal cancer and to improve the prognosis of the disease, through the use of a mobile application. VHIR and Anaxomics signed recently an agreement to provide the use of systems biology techniques to research groups from Vall d’Hebron, allowing the application of this innovative approach in the usual clinical practice. The profile analysis of a patient through systems biology techniques is commonplace in world renowned hospitals, such as Memorial Sloan-Kettering Cancer Center or Mount-Sinai in New York, where it forms part of a protocol of treatment assignment for patients with certain cancers. One of the problems that doctors and researchers share is how to integrate all the apparently unconnected data from each patient, and here is where Anaxomics goes into action. Its technology, based on systems biology, allows the integration of all this data into mathematical models that simulate, in silico, the behavior of the human physiology. According to the VHIR’s director, Dr. Joan X. Comella, this type of technology “is essential to foster a better understanding of the molecular mechanisms whose alteration is the origin of different pathologies, and also to improve the personalized treatment of the patients according to their personal characteristics". Systems biology allows the integration in a single analysis of all the information of patients, including both clinical data (clinical profile, received treatments, results of routine marker analysis) and “omics” data obtained in proteomics, genomics and metabolomics studies, whose cost per patient is constantly decreasing and which many times becomes indispensable for research projects. The integration of this huge quantity of data and its later interpretation require very specific tools and knowledge. </td></tr></table>comunica@vhir.org (VHIR)Thu, 27 Feb 2014 00:00:00 GMTCome to the first VHIR Science Beer! (27/02/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=39&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0039\2014_0039_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> We invite you to attend the first Science Beer organized by Vall d'Hebron Research Institute (VHIR), this Thrusday 27. This new talk format is based on interdisciplinary dialogue of any current scientific matters among recognized experts of three different but complementary areas. With dynamism, plain language and an informal tone, the guest speakers will introduce briefly some ideas for debate. The audience will then be invited to join the conversation with questions and open direct discussions with the guests, thus allowing closeness between them and enjoying the privilege to have first rate experts to satisfy their queries. Science Beer opens the door to an innovative format in citizen’s science with the collaboration of Cervezas Moritz and TheDoctorFactory. The first Science Beer is titled 'How to achieve an eight-thousander' and aims to generate a discussion focusing on the challenge of the eight-thousanders, from the point of view of a mountaineer and a researcher: which principles are shared, how the passion for a challenge becomes a lifestyle, and a long list of exciting angles that will cross-over amongst the audience and the three guests: Ferran Latorre, climber. His challenge is to achieve the 14 eight-thousanders, and he has already reached the summit of 9. Joan Montaner, Coordinator of Neuroscience Area and Head of the Neurovascular Research Group at VHIR. He is a leading European expert in stroke research. Mara Dierssen, Leader of Research Group Cellulars &amp; Systems Neurobiology at CRG and President of the Spanish Society of Neuroscience. She is a leading neuroscientist worldwide in the field of Down Syndrome. The talk will be followed by a concert by music group FromLosttotheRiver (Luis de Rojas, Pablo Reche, Ignasi Cuadern, Oriol Roige and Mara Dierssen). <p style=" text-align: left; text-indent: 0px; padding: 0px 0px 0px 0px; m</td></tr></table>comunica@vhir.org (VHIR)Thu, 27 Feb 2014 00:00:00 GMTResearchers and residents of the Vall d'Hebron address the challenges in the management of critical oncologic and hematologic patients (25/02/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=49&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0049\2014_0049_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Researchers of the Vall d’Hebron Research Institute (VHIR) and residents of the hospital have participated in the II Meeting of Severe Infection in Oncohematological Patients, held last week between the Saint Louis Hospital in Paris, Son Llàtzer Hospital in Mallorca and Vall d’Hebron University Hospital, in Barcelona. By means of an international videoconference, Dr. Rello, Head of the Intensive Care Service and the Clinical Research/Innovation in Pneumonia &amp; Sepsis Group (CRISP) at VHIR, opened the meeting focused on the main challenges to improve survival in critical oncohematological patients. During the session, that could be followed live from the website of the Spanish Society of Intensive and Critical Care Medicine and Coronary Units, were also presented collaborative studies and clinical cases.&nbsp; </td></tr></table>comunica@vhir.org (VHIR)Tue, 25 Feb 2014 00:00:00 GMTVHIR opens the registrations for the Master Degree in Translational Biomedical Research (25/02/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2013&num=276&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2013\2013_0276\2013_0276_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Vall d’Hebron Institute of Research will start on October 2014 the first edition of the new Master in Translational Biomedical Research, affiliated to Universitat Autònoma de Barcelona. The aim of the programme is to generate excellent young researchers by providing them with the necessary combination of scientific and medical knowledge and skills to contribute successfully to the future of translational medical research. The master is addressed to research career, providing access to a PhD programme related to the biomedicine area that they had previously chosen for the training programme and internship. At the end of the course, students will have the tools and the skills to be able to turn the knowledge into clinical applications, treatments and better diagnostics methods for improving patients' heath. The main feature of this master programme is that takes place in a research institute recognized as Instituto de Investigación Sanitaria by the Instituto de Salud Carlos III, an organism depending of the Spanish Government. All the classes will be given at VHIR during the first semester by basic, clinical researchers and medical doctors who are in continuous contact with patients. The second semester will be devoted to the the master’s project and the practice internship that could be carried out in one of the 60 research groups from the 10 research areas of the Institute. Registrations are already open and first candidates will be accepted on April. For additional informati</td></tr></table>comunica@vhir.org (VHIR)Tue, 25 Feb 2014 00:00:00 GMTComputed tomography or cardiac catheterization? (24/02/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=47&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0047\2014_0047_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Scientists from 28 research facilities in 20 European countries were meeting from February 11 until 13 in Berlin to kick off the collaborative research project DISCHARGE. The purpose of this project, which is coordinated by Charité, is to determine for which patients with chest pain cardiac computed tomography (CT) or cardiac catheterization is best suited. The DISCHARGE project received six million Euros of funding from the European Union for five years. In Europe, approximately 3.5 million cardiac catheterizations are performed each year. However, 50 to 60 percent of these minimally invasive examinations do not result in any further treatment. Prof. Dr. Marc Dewey from the Department of Radiology at Charité coordinates the project and will examine together with his 28 partners, among them Dr. José Rodríguez Palomares from Vall d’Hebron Institute of Research (VHIR), whether or not non-invasive CT of the heart is an effective procedure in diagnosing or excluding coronary artery disease. This could be beneficial for patients in two ways: patients would be exposed to lower risks due to the non-invasive nature of CT, and the examination itself is less burdensome and can be carried out on an outpatient basis. “Given the broad scope of our DISCHARGE collaborative research, we expect to achieve conclusive results, which will directly impact practice in cardiovascular medicine. We very much hope that our findings can contribute to improving medical care for cardiac patients”, commented Prof. Dewey at the start of the project. Dr. Rodriguez Palomares added that the study is important taking into account the current economic situation, since “it will demonstrate the usefulness of less invasive diagnostic techniques for patients with lower cardiovascular risk; consequently, resources will be optimized and the rate of complications in the management of the different groups of patients reduced”. </td></tr></table>comunica@vhir.org (VHIR)Mon, 24 Feb 2014 00:00:00 GMTA jungle, a coral reef, a mosquitoe crushed in glass... and you, what do you see in our exhibition? (21/02/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=46&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0046\2014_0046_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Science is rigor, technique, method, patience. But also creativity, curiosity, imagination, passion and ingenuity to search without prejudices, and to allow room for surprise. We invite to join this path towards the unknown, the uncertainty. We ask you to give free rein to your imagination and help us complete the fantasy that the pictures taken in our labs suggest. The first visitors to the exhibition at Lluïsos de Gràcia have already travelled with us to this surprising world hidden in the most remote parts of our body. Guess what have they seen: a jungle, a Gaudí’s wall, the Moon surface, an evil eye bead, a pierced walnut, a coral reef, a butterfly, a fish, a mosquitoe crushed in glass, a party with balloons… Visit our Facebook and Twitter profile to take a look at these pictures and give your impressions about them. The most original will be invited to a surprise tour! And don’t forget that the exhibition will be open until March 9th at Lluïsos de Gràcia. Watch the pictures on this link </td></tr></table>comunica@vhir.org (VHIR)Fri, 21 Feb 2014 00:00:00 GMTVall d'Hebron's Oncology Service is included in an exclusive consortium for clinical trials by GSK (20/02/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=43&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0043\2014_0043_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The pharmaceutical company GlaxoSmithKline (GSK) has selected the Oncology Service of Vall d’Hebron University Hospital as one of the six international renowned members of the Oncology Clinical and Translational Consortium (OCTC). The new network will provide collaborations in oncology research focused towards the development of the next generation of novel oncology therapeutics. The participants of the consortium will have access to GSK’s studies in early stages of the clinical development, as well as to translational and preclinical studies. The centers will also design and execute research programs in a focused and expeditious way, allowing the development of new diagnostic tools and medicines to better treat cancer patients. The other five centers of the study are Gustave Roussy (France), the University of Texas MD Anderson Cancer Center (USA), the Memorian Sloan-Kettering Cancer Center (USA), el Netherlands Cancer Institute (Netherlands) and the Princess Margaret Cancer Centre University Health Network (Canada). All of them, together with Vall d’Hebron, will collaborate on processes to ensure the highest quality standards for collection of biological samples, as well as conduct of biomarker and clinical research.  </td></tr></table>comunica@vhir.org (VHIR)Thu, 20 Feb 2014 00:00:00 GMTResearchers in Bioinformatics move to the new 'Mòdul VHIR' (19/02/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=45&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0045\2014_0045_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Statistics and Bioinformatics Unit (UEB) and the Translational Bioinformatics in Neuroscience research group, led by Dr. Xavier de la Cruz, have been relocated to 'Mòdul VHIR'. The same facilities will host Dr. Chaysavanh Manichanh, together with Xavier Martínez, from the Physiology and Pathophysiology of the Digestive Tract group, and Josep Gregori, researcher from the Liver Diseases group. Since the beginning of the year, Vall d’Hebron Institute of Research (VHIR) has this module of two floors of 170m2, located in front of the Mother and Child Hospital and next to the blood bank. The module will be also the site of Works Council, and will host two rooms for -80ºC freezers </td></tr></table>comunica@vhir.org (VHIR)Wed, 19 Feb 2014 00:00:00 GMTNew blood cells fight brain inflammation in multiple sclerosis (18/02/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=44&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0044\2014_0044_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Hyperactivity of our immune system can cause a state of chronic inflammation. If chronic, the inflammation will affect our body and result in disease. In the devastating disease multiple sclerosis, hyperactivity of immune cells called T-cells induce chronic inflammation and degeneration of the brain. Researchers at the Biotech Research &amp; Innovation Centre (BRIC) of the University of Copenhagen, and the Centre of Multiple Sclerosis of Catalonia (Cemcat), led by Dr. Xavier Montalban and Dr. Manuel Comabella, have identified a new type of regulatory blood cells that can combat such hyperactive T-cells in blood from patients with multiple sclerosis. By stimulating the regulatory blood cells, the researchers significantly decreased the level of brain inflammation and disease in a biological model. The results were published on Sunday in the journal Nature Medicine. The new blood cells belong to the group of our white blood cells called lymphocytes. The cells express a molecule called FoxA1 that the researchers found is responsible for the cells’ development and suppressive functions. “We saw that FoxA1 cells play an important role in both the animal model of multiple sclerosis (experimental autoimmune encephalomyelitis), by suppressing the clinical course of the disease when it is induced, and multiple sclerosis, where its expression is induced by interferon-beta, which is one of the most used treatments for the disease”, reports Dr. Comabella, researcher from the Neuroimmunology group at Vall d’Hebron Institute of Research (VHIR) and Cemcat. In the case of the nearly 30 patients from Cemcat included in the study and treated with interferon-beta, they discovered that those who presented a good clinical response had a higher induction of FoxA1 cells. According to him, “further knowledge of this immunosuppressive population could be the starting point for the design of new effective treatments for multiple sclerosis based on cell therapy”. Genzyme awards another project of Dr. Comabella <span sty</td></tr></table>comunica@vhir.org (VHIR)Tue, 18 Feb 2014 00:00:00 GMTThe Infectious Diseases group is awarded by the ESCMID (17/02/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=42&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0042\2014_0042_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) has awarded one of the 2014 Research Prize to support the project entitled "PLGA nanoparticles as carriers for specific delivery of nebulized antibiotic drug combinations against respiratory infections Caused by High -risk clones of P. aeruginosa in the murine model", presented by Dr. Yolanda Meije from the Infectious Diseases Group at Vall d’Hebron Institute of Research (VHIR). The project is part of a novel research line led by Dr. Joan Gavaldà and Dr. Albert Pahissa. The study is based on the use of nanotechnology in order to fight off respiratory infections caused by multi-resistance microorganisms. VHIR researchers will administrate nebulized antibiotic drugs combinations with the aim to get bigger drug concentrations in the lung, to avoid the side effects of a systemic treatment and to increase the treatment’s efficacy. The incidence of infections by multi-resistance microorganisms is around the 25% in the EU, the responsible of nearly 25,000 deaths per year, and it costs to the system €1.5 billion per year. Dr. Meije regrets that despite the high incidence of these infections, “less than the 5% of the products of R&amp;D developed worldwide are new antibiotic drugs for the treatment of these infections which don’t currently have many therapeutic options”. This research work, funded by the ESCMID with 20,000 euros, has been developed in a multidisciplinary way with Dr. Eduard Torrent of The Institute for Bioengineering of Catalonia (IBEC) and Dr. Antonio Oliver, Head of The Microbiology Department at Son Espases Hospital in Mallorca. </td></tr></table>comunica@vhir.org (VHIR)Mon, 17 Feb 2014 00:00:00 GMTEye drops to prevent diabetic retinopathy and a continuous automatic bladder irrigation system win the Innovation Contest (13/02/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=38&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Vall d’Hebron University Hospital has hosted the ceremony awards of the first Innovation Contest VHIR-HUVH. The winner of the general category, with 5,000 euros, has been the project “Development of eye drops to treat diabetic retinopathy: from experimental research to clinical application”, led by Dr. Rafa Simó, whereas the first position of the nursing category has been for the project “Continuous automatic bladder irrigation system”, coordinated by Montserrat Llinàs. The project “Visual reinforcement on physiotherapy”, led by Isabel Martín, has been awarded with the 2,500 euros of the second prize of nursing, and the project “Apataxina as a new biomarker of response to irinotecan in patients with colorectal cancer”, led by Dr. Diego Arango. The technical committee has also recognized the project “Biopsy punch with storage integrated”, led by Mireia Ruiz. The Knowledge Transfer and Innovation Unit at Vall d’Hebron Institute of Research (VHIR) has organized this contest sponsored by Roche, with the aim to detect the knowledge generated in the labs and the hospital, in order to monitor it, protect it and transfer it to the market. Nearly 50 projects have been assessed by a technical committee of representatives from VHIR, the Nursing Management Area at HUVH, Biocat, Ysios, the medical board of Barcelona, RCD, Trifermed, Arvor and Metasbio. The opening of the awards ceremony has been led by Dr. Carles Constante, director of regulation, planning and health of the Catalan</td></tr></table>comunica@vhir.org (VHIR)Thu, 13 Feb 2014 00:00:00 GMTIdentified a biomarker that predicts survival in patients with the most frequent renal cancer (12/02/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=36&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0036\2014_0036_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Researchers from the Kidney Physiopathology group from CBBIM-Nanomedicine at Vall d’Hebron Institute of Research (VHIR), in collaboration with Service of Urology and Anatomical Pathology of the Vall d’Hebron University Hospital, have identified for the first time a new biomarker, the pstat-3 Ser727, present in tumors of clear cell renal cell carcinoma (ccRCC), which predicts the survival of patients. The study, published in Cancer Research, may represent a paradigm shift in the care and treatment of patients. "The apparently benign tumor can be as serious as the more invasive if biomarker levels are high", warns Dr. Anna Meseguer, leader&nbsp; of the group, after confirming the results obtained in vitro in a cohort of 98 ccRCC patients treated at Vall d'Hebron, with more of five years of clinical follow-up. From the presence of the biomarker in a tumor sample, researchers have found that "tumors classified in the same risk group and apparently similar can behave very differently and determine the survival of patients, which can vary between 17 and 70 months", according to the lead author of the study, Dr. Meseguer. </td></tr></table>comunica@vhir.org (VHIR)Wed, 12 Feb 2014 00:00:00 GMTVall d’Hebron starts a clinical trial to test a drug against acute myeloid leukemia (11/02/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=35&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0035\2014_0035_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The biotech company Oryzon has started this week at Vall d’Hebron a new clinical trial of Phase I with ORY-1001, a new drug developed by international researchers in the last 5 years. According to a press release by the company, the new drug is an inhibitor of LSD1 which has already proved in animals that can trigger programmed cell death (apoptosis) in leukemic stem cells, without affecting healthy hematopoietic progenitors. It can also induce normal blasts maturation. The clinical trial is led by Dr. Francesc Bosch, head of the Hematology Service at the Hospital and the Hematology research group at Vall d’Hebron Institute of Research (VHIR). Dr. Olga Salamero, responsible of the Leukemia Unit and researcher from the same group at VHIR, says that during the first phase, “the drug will be administered in over 30 patients with acute myeloid leukemia and any other effective treatment”. Researchers will study the effects and toxicity of this new drug that will be tested for the first time in humans, until the first semester of 2015. During the following months, more Spanish and British hospitals will recruit patients for the clinical trial. </td></tr></table>comunica@vhir.org (VHIR)Tue, 11 Feb 2014 00:00:00 GMTVall d'Hebron becomes a preferred investigation site of Bristol-Myers Squib (10/02/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=32&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0032\2014_0032_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Vall d’Hebron University Hospital (HUVH) has signed an agreement with Bristol-Myers Squibb (BMS) to become one of its preferred investigation sites to support its clinical trial book of work. This is a collaboration of mutual respect for the complementary skills of each organization, and will be driven by an alignment in goals to support drug development. This partnership demonstrates core principles of innovation, transparency and a commitment to quality, strong performance and continuous improvement. BMS is a Biopharma Company committed to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. They commit to scientific excellence and investment in biopharmaceutical research and development to provide innovative, high-quality medicines that address the unmet medical needs of patients with serious diseases. BMS is signing agreements with the best investigational sites. HUVH, the biggest hospital of Catalonia, is the leader of clinical trials in Spain, a reference in biomedicine research, and is signing preferential agreements with the best Biopharma Companies. </td></tr></table>comunica@vhir.org (VHIR)Mon, 10 Feb 2014 00:00:00 GMTVHIR participates in the European Training Network 'NeuroGut' (07/02/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=31&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0031\2014_0031_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The European Union has approved funding of an Initial Training Network (ITN) NeuroGut for 4 years, with a total financial volume of 3.7 M € from the 7th Framework Programme. This is among the first such training networks in gastroenterology and it is devoted to "neural regulation of intestinal functions". It includes ten academic partners and two companies from 9 European countries, and in Spain is coordinated by Dr. Fernando Azpiroz and Dr. Javier Santos, from the Physiology and Pathophysiology of the Digestive Tract group at Vall d'Hebron Institute of Research (VHIR). ITNs of the EU are educational programs for doctoral students in specialized areas that have received insufficient representation in conventional academic curricula because of their borderline existence between different specialties. During the following 3 years, the Physiology and Pathophysiology of the Digestive Tract group at VHIR will train a European predoctoral researcher from outside Spain in Neurogastroenterology. For Dr. Santos, "it is a great opportunity to do further research in these common gastrointestinal diseases that are so connected with the brain, such as the stress with the Irritable Bowel Syndrome". Neurogastroenterology is a subspecialty of gastroenterology and investigates the influence of the nervous system (the central, the autonomic, and the enteric nervous system) on functions of the gastrointestinal tract (motility, secretion, absorption) and their dysfunctions, infections, and inflammation in disease states, but also with the effects of normal and abnormal functions on health, nutrition and psychological wellbeing. A special emphasis will be the role of the gut microbiome in gut-brain-gut interactions. The project will start with a kick-off meeting in Berlin on February 22st. </td></tr></table>comunica@vhir.org (VHIR)Fri, 7 Feb 2014 00:00:00 GMTExploring alternative sources to fund research (06/02/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=30&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0030\2014_0030_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Which roles play the medical societies and the patient’s association in the funding of science? How can we contribute with the private sector to get funds for research? What is behind crowdfunding? All these questions have been discussed in the first sessions of the FCIS Cerdanyola Meeting, hosted on Thursday in the Auditorium of the Parc Tecnològic del Vallès. The director of Vall d’Hebron Institute of Research (VHIR) and secretary-general of the Spanish Confederation of Scientific Societies (COSCE), Dr. Joan X. Comella, showed the case of VHIR as an example of how to keep all the activity and the growth, despite the cuts of the Spanish Government in research grants. For this, he assures, it is essential to diversify: “Regarding the funding sources, the monoculture of public subsidies is a high-risk strategy because the possibilities of extinction are too high if we lose them. For that reason, we have to diversify by fostering public and private partnerships, the internationalization, the capital risk and the innovation”. In this case, he reported how the Institute has maintained its numbers thanks to the increase of the incomes for clinical trials, international calls and different agreements with companies. Regarding the opportunities of raising funds from the private sector, the responsible of fundraising at VHIR, Carmen Netzel, explained the collaborations of the Institute with companies or entities not related with biomedical research, such as Vodafone Foundation, Industex and Josep Palau I Francàs Foundation. According to a recent study carried out by the Spanish Association of Fundraising, in Spain there are more than 16,000 foundations (the 30% are established in Catalonia) with an overall turnover of 1,200M euros. A sector which is undergoing a restructuration, but it offers a lot of opportunities for funding research projects. The major of Cerdanyola del Vallès, Carme Carmona, has organized this first meeting, together with the rector of the Universitat Autònoma de Barcelona, Dr. Ferran Sancho, and Dr. Pere Gascón, head of the Oncology Service at Hospital Clinic, as a president of the scientific committee. <a style=" font-size: 8pt;</td></tr></table>comunica@vhir.org (VHIR)Thu, 6 Feb 2014 00:00:00 GMTDiscover what researchers see and create (03/02/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=23&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0023\2014_0023_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> “Research in the forefront: discover what researchers see and create”; this is the title of the exhibition that Lluïsos de Gràcia will host from the 11th of February to the 9th of March with the best pictures taken from the last three editions of the scientific photo competition of Vall d’Hebron Institute of Research (VHIR). The exhibition features 18 stunning pictures, most of them obtained by the state-of-the-art microscopes that reveal impressive hidden parts of our body, such as the peculiar shape of the intestinal surface and the cells which allow heart contractions. This exhibition is the first event organized by VHIR for its 20th anniversary. Don’t miss it, admission is free! Place: Plaça del Nord 7-10, Barcelona (Metro L3 Lesseps) Dates: 11th of February – 9th of March Schedule: Monday-Friday 5PM-11PM. Saturdays 9AM-11PM. Sundays 9AM-2PM and 5PM-9PM. </td></tr></table>comunica@vhir.org (VHIR)Mon, 3 Feb 2014 00:00:00 GMT